Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1562

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 15
Chunk 1562
---
, 2024 options exercisable totaled 2,348,720. The Company recognized approximately $1.9 million in stock-based compensation
in 2024. There was approximately $1.5 million of unrecognized compensation cost related to unvested share-based compensation awards granted.
These costs will be expensed through the second quarter of 2026.

    F-17

MIRA
                                            PHARMACEUTICALS, INC.

NOTES
TO THE FINANCIAL STATEMENTS

DECEMBER
31, 2024 AND 2023

The
following is option activity during the year ended December 31, 2024 and 2023:

 Schedule of Stock
Option Activity

    Number
    of Shares  
    Weighted
    Average Exercise Price Per Share  
    Weighted
    Average Remaining Contractual Life (Years)  
    Aggregate
    Intrinsic Value 

    Outstanding
    as January 1, 2023  
     750,000  
    $5  
     9.4  
    $-- 
  
    Options
    granted  
     635,001  
    $5.55  
     -  
    $- 
  
    Forfeitures 
     (170,000) 
    $5  
     -  
    $- 
  
    Outstanding
    as December 31, 2023 
     1,215,001  
    $5.29  
     8.7  
    $- 
  
    Options
    granted  
     3,599,000  
    $1.15  
     -  
    $- 
  
    Expired 
     (268,886) 
    $5.05  
     -  
    $- 
  
    Forfeitures 
     (309,449) 
    $4.68  
     -  
    $- 
  
    Outstanding
                                            as December 31, 2024  
     4,235,666  
    $1.83  
     9.2  
    $135,200 
  
    Exercisable,
                                            December 31, 2024  
     2,348,720  
    $2.23  
     8.6  
    $120,886 

Key
assum